XGN Exagen

Exagen to Participate in 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

Exagen to Participate in 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that its management team will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 15-17, 2020.  Ron Rocca, President and CEO of Exagen, will engage in a fireside chat on September 15 at 2:40 pm EDT.

A link to the live webcast of Mr. Rocca’s fireside chat will be available online from the investor relations section of the Exagen website at .  Following the live webcast, a replay of the event will be archived on the Exagen website for approximately 90 days.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on its proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

CONTACTS:

Investors

Westwicke Partners

Mike Cavanaugh



646.677.1838



Company Contact

Exagen Inc.

Kamal Adawi, Chief Financial Officer



760.477.5514

EN
03/09/2020

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhanc...

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics...

June 23, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Announces Closing of $20.2 Million Public Offering Includi...

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of...

May 9, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Prices Public Offering of Common Stock

Exagen Inc. Prices Public Offering of Common Stock CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day opt...

May 8, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Announces Proposed Public Offering of Common Stock

Exagen Inc. Announces Proposed Public Offering of Common Stock CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exagen. The offering is subject to ma...

May 7, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average...

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.   Three Months Ended March 31,   2025   2024 (in thousands, except ASP data)  Revenue $15,498  $14,415 Gross margin  58.9%  59.6%Operating expenses $12,488  $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch